Preventive migraine therapy: what is new.
In this paper we review new treatment options for migraine prevention. Because we focus on new drugs, some of the data we present herein were acquired in well design double blind, controlled studies, while the efficacy of other medication is supported only by open, uncontrolled trials (noted in the text wherever appropriate).
Rapoport
A M
AM
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Bigal
M E
ME
D000700:Analgesics / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D001905:Botulinum Toxins / Q000627:therapeutic use; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003067:Coenzymes; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D017706:Lisinopril / Q000627:therapeutic use; D008881:Migraine Disorders / Q000503:physiopathology / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D036901:Petasites; D008517:Phytotherapy; D010879:Piperazines; D013777:Tetrazoles / Q000627:therapeutic use; D000077236:Topiramate; D014230:Triazoles / Q000627:therapeutic use; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000700:Analgesics; D000806:Angiotensin-Converting Enzyme Inhibitors; D018687:Antidepressive Agents, Second-Generation; D000975:Antioxidants; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D003067:Coenzymes; D018696:Neuroprotective Agents; D010879:Piperazines; D013777:Tetrazoles; D014230:Triazoles; D000077236:Topiramate; D014451:Ubiquinone; D005632:Fructose; C051752:nefazodone; C023754:tizanidine; D017706:Lisinopril; D001905:Botulinum Toxins; C024989:coenzyme Q10; D003000:Clonidine; C081643:candesartan